Letter to the Editor
Real-world outcomes of chemotherapy in pancreatic cancer: considerations for validity and interpretation
Annals of Pancreatic Cancer
2026;
9:
7
.
(30 January 2026)
Letter to the Editor
Improving long-term outcomes in resectable pancreatic cancer
Annals of Pancreatic Cancer
2026;
9:
6
.
(30 January 2026)
Original Article
Estimation of symptoms burden in advanced pancreatic cancer patient and impact of palliative care intervention on it
Annals of Pancreatic Cancer
2026;
9:
5
.
(30 January 2026)
Editorial Commentary
Optimal management of resectable pancreatic ductal adenocarcinoma
Annals of Pancreatic Cancer
2026;
9:
4
.
(30 January 2026)
Letter to the Editor
FOLFIRINOX for pancreatic cancer: a real-world registry analysis
Annals of Pancreatic Cancer
2026;
9:
3
.
(30 January 2026)
Editorial Commentary
Defining risk-adapted adjuvant therapy in resectable pancreatic cancer: an editorial commentary on long-term outcomes from ESPAC4
Annals of Pancreatic Cancer
2026;
9:
2
.
(30 January 2026)
Editorial Commentary
ESPAC-4 long-term follow-up: shall we choose gemcitabine and capecitabine as adjuvant therapy for elderly and low-risk pancreatic adenocarcinoma following surgical resection?
Annals of Pancreatic Cancer
2026;
9:
1
.
(30 January 2026)